Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies

Chimeric antigen receptor (CAR) T-cell therapy has emerged recently as a standard of care treatment for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) and several subtypes of B-cell non-Hodgkin lymphoma (NHL). However, its use remains limited to highly specialized centers, g...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Harjeet, Srour, Samer A., Milton, Denái R., McCarty, Jessica, Dai, Cuiping, Gaballa, Mahmoud R., Ammari, Mariam, Olivares, Simon, Huls, Helen, De Groot, Eleanor, Marin, David, Petropoulos, Demetrios, Olson, Amanda L., Anderlini, Paolo, Im, Jin S., Khouri, Issa, Hosing, Chitra M., Rezvani, Katayoun, Champlin, Richard E., Shpall, Elizabeth J., Cooper, Laurence J. N., Kebriaei, Partow
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684710/
https://www.ncbi.nlm.nih.gov/pubmed/36439104
http://dx.doi.org/10.3389/fimmu.2022.1032397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684710/
https://www.ncbi.nlm.nih.gov/pubmed/36439104
http://dx.doi.org/10.3389/fimmu.2022.1032397

Ejemplares similares